Question 1

Which countries lead Head and Neck Cancer Studies research?

Accepted Answer

By volume, China and the United States publish the most (2.5k and 2.4k works in 2022-now).

Question 2

Which institutions lead Head and Neck Cancer Studies research?

Accepted Answer

By volume in 2022-now, Sun Yat-sen University publishes the most Head and Neck Cancer Studies research, followed by Harvard University and Sichuan University.

Question 3

Who are the leading researchers in Head and Neck Cancer Studies?

Accepted Answer

The most-cited researchers publishing on Head and Neck Cancer Studies include Ahmedin Jemal, Christopher J L Murray and Rebecca L. Siegel.

Question 4

Where is Head and Neck Cancer Studies research done?

Accepted Answer

The largest centres of Head and Neck Cancer Studies research in 2022-now are Guangzhou (China), Beijing (China), Shanghai (China) and Chennai (India). Among places with at least 20 works in it, it is an unusually large share of all research in Plainview and Kashiwa.

Question 5

Where is the best place to study Head and Neck Cancer Studies?

Accepted Answer

Among universities, judged by research, Sun Yat-sen University, Humanitas University and University of Groningen score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

Question 6

Is Head and Neck Cancer Studies research growing?

Accepted Answer

Output in 2022-2025 was 8% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Head and Neck Cancer Studies.

Question 7

What are the most cited papers in Head and Neck Cancer Studies?

Accepted Answer

The most cited paper in Head and Neck Cancer Studies is "Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer" (K. Kian Ang, Jonathan Harris, Richard H. Wheeler et al., 2010), with 6,617 citations. Next come "Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer" (6,330) and "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck" (5,189).